BNOS 2015 Annual Conference

EMCC Nottingham 1st - 3rd July 2015

**JTV Video Clips**

**Wednesday 1st July 2015**

11.00 Welcome, introduction and objectives for training session
   Professor David A Walker, BNOS Chair

11.10 - 12.25 **Session 1 - What's new for children and TYAC (0-24 years)? To include MDT, highlighting uncertainty in diagnosis**
   Chair: David Walker
   - Epidemiology, health service provision and outcomes
     Martin McCabe
   - MDT case discussion
     Lead: Richard Grundy
   - New hope for next 2/3 years
     Richard Grundy

12.25 - 13.15 **Lunch and poster viewing**

13.15 - 14.30 **Session 2 - What’s new in adult brain tumour management (25-70 years)? To include MDT, highlighting issues with LGG progression**
   Chair: David Walker
   - Epidemiology, health service provision and outcomes
     Andrew Brodbelt
   - MDT case discussion
     Lead: Colin Watts
   - New hope for next 2/3 years
     Paul Mulholland

14.30 - 15.00 **Coffee and poster viewing**

15.00 - 16.15 **Session 3 - What’s new for brain tumours in later life (over 70 years)? To include MDT, highlighting issues with therapy benefits in an elderly patient**
   Chair: David Walker
Epidemiology, health service provision and outcomes  
Andrew Brodbelt

MDT case discussion  
Lead: Stuart Smith

New hope for next 2/3 years  
Speaker tbc

16.30  
Formal opening  
Professor Sir David Greenaway, Vice Chancellor, University of Nottingham

16.45 - 17.30  
Plenary speaker: Henry Marsh CBE, Consultant Neurosurgeon, St George's Hospital, London  
Evidence and low grade gliomas

17.30 - 17.45  
Robin Grant, Edinburgh Cancer Research Centre  
James Lind Alliance Priority Setting Partnership: The UK Top 10 clinical research priorities in Neuro-Oncology

17.45 - 18.45  
Session 1 - Oral poster session  
Members proffered presentations

19.30  
Welcome reception (Wollaton Hall)

19.30  
Buses will depart from EMCC from approx. 19.15 onwards

Thursday 2nd July 2015

08.50 - 9.00  
Welcome  
Professor David A Walker, President, BNOS

09.00 - 10.20  
Session 2 - Tumour invasion and metastasis  
Chair: David Walker & Beth Coyle

09.00 - 9.40  
Plenary lecture: Jonathan Finlay, Professor of Paediatrics & Director, Neuro-Oncology Programme, Nationwide Children’s Hospital, Columbus, Ohio  
Adolescent & adult medulloblastoma; time for a change in management

09.40 - 09.50  
Dr Julia Cockle, Leeds Institute of Cancer Studies & Pathology
Oncolytic herpes simplex virus inhibits paediatric high grade glioma and diffuse intrinsic pontine glioma migration and invasion; mechanism and potential for clinical application

Mr Jorrit De Waele, University of Antwerp

3D culture of murine neural stem cells on de-cellularized mouse brain sections

Miss Durgagauri Sabnis, CBTRC, University of Nottingham

Functional analysis of multi-drug resistance transporter ABCB1 which correlates with poor prognosis in paediatric ependymoma

Mr Jiun-Lin Yan, University of Cambridge

Characterising tissue anisotropy of the peri-tumoural region in glioblastoma using diffusion tensor imaging

Coffee and poster viewing

Session 3 - Therapy related brain injury
Chair: Robin Grant & Mathilde Chevignard

Stephen Baker Memorial Lecture (Sponsored by The Brain Tumour Charity): Michael Weller, Chair & Professor of Neurology, University Hospital Zurich & EANO President
The future of glioma therapy: beyond radiotherapy, PCV & temozolomide

Mrs Iona Darge, Oxford University Hospitals NHS Trust

Oxford Neuro-Oncology Integrated Rehabilitation Service: Living life not just surviving

Professor David Walker, CBTRC, University Of Nottingham

Delayed diagnosis of paediatric CNS tumours - Headsmart Be Brain Tumour Aware
11.50 - 12.00 Dr Emily Bennett, Nottingham University Hospitals NHS Trust
The early impact of an innovative multidisciplinary team to neuro-rehabilitation for children with a brain tumour

12.00 - 12.10 Dr Rob Dineen, University Of Nottingham
Development of a potential pre-operative risk stratification tool of cerebellar mutism syndrome in children with posterior fossa tumour

12.10 - 13.40 Lunch (Poster viewing and judging by panel for Session 4 short oral presentations)

12.20 - 13.20 Novartis-sponsored session (MDT style)
Finbar O'Callaghan, Gurminder Mann, Sophie Wilne, Pichaya Petborom, Richard O'Neill, Jacqueline Eason

12.20 - 13.20 Neuro-Oncology CRG Meeting

13.40 - 15.00 Session 4a - Tumour characterisation
Chair: Sebastian Brandner & Richard Grundy

Ephrin-B2 drives perivascular invasion and tumorigenicity of glioma stem cells and is a therapeutic target for glioblastoma

14.20 - 14.30 Professor Sebastian Brandner, UCL Institute of Neurology
Establishing a diagnostic pipeline for methylome analysis of paediatric and adult brain tumours in the UK using the Heidelberg classifier

14.30 - 14.40 Dr Farhana Haque, CBTRC, University Of Nottingham
New tools to study histone H3.3 mutations in DIPG
and pHGG

14.40 - 14.50 Dr Ningning Li, UCL Institute of Neurology
(Abstract 15) Identification of novel signalling pathways associated with mutant IDH1

14.50 - 15.00 Dr Sara Piccirillo, University of Cambridge
(Abstract 104) Genetic and functional diversity of propagating cells in glioblastoma

13.40 - 15.00 **Session 4b - Transition from childhood to adult services and support**
Chair: Ingela Oberg & Margaret Parr

13.40 - 14.20 Plenary lecture: Mathilde Chevignard, Physical & Rehabilitation Medicine Physician, Hôpitaux de Saint Maurice, France (Sponsored by CCLG)
Rehabilitation for children and young people with brain tumours and transition to adult services

14.20 - 14.30 Mrs Kathy Dickinson, East Midlands Children & Young Persons’ Integrated Cancer Service
(Abstract 7) Moving on

14.30 - 14.40 Dr Alexandra Gaskill, Sussex Partnership NHS Trust
(Abstract 9) Treatment for a Brain Tumour: An Interpretative Phenomenological Analysis Approach

14.40 - 14.50 Dr Emily Bennett, Nottingham University Hospitals NHS Trust
(Abstract 49) Supporting children and young people with a brain tumour to return to school: the creation of an innovative, inter-agency pathway

14.50 - 15.00 Mrs Louise Robinson, East Midlands Children & Young Persons Integrated Cancer Service
(Abstract 88) Neuro oncology parent’s awareness day
15.00 - 15.30  *Coffee and poster viewing*

15.30 - 17.30  **Session 5 - New treatments in development and drug delivery**  
**Chair: Michael Weller & Richard Grundy**

Plenary lecture: Katherine Warren, Head - Paediatric Oncology Section, National Cancer Institute, Bethesda, USA  
How Do We Rationally Go from Bench to Bedside? The Dilemma of DIPG.

15.30 - 16.10  Dr Matthew Baker, University of Strathclyde  
(Abstract 10) Developing stratified serum spectroscopic diagnostics for brain tumours: Finding the features

16.10 - 16.20  Miss Durgagauri Sabnis, CBTRC, University Of Nottingham  
(Abstract 101) Druggable prognostic markers in paediatric ependymoma; is Blbp the solution?

16.20 - 16.30  Mr Abhijit Patil, University of Sheffield  
(Abstract 43) Identification of novel small molecule inhibitors of the Fanconi Anaemia DNA repair pathway as a means to sensitises glioblastomas to chemotherapeutic agents

16.30 - 16.50  Dr Stuart Smith, CBTRC, University Of Nottingham  
(Abstract 102) Simultaneous intra-cavity delivery of multiple neurotherapeutics from a mouldable neurosurgically-applied polymer paste

16.50 - 17.30  Best poster oral presentations

18.30 - 19.45  ‘Question Time’- style debate: ‘Are brain tumour services in UK comparable to the rest of Europe?’  
Chair: Peter Homa (Chief Exec, Nottingham University Hospital HNS Trust)  
Panellists include: Michael Weller, Henry Marsh, Paul Grundy, Jacqueline Cornish, Kathy Oliver, Geoff Pilkington
20.00 - 23.00  Conference dinner (Main Hall, EMCC)

**Friday 3rd July 2015**

09.00 - 10.30  Session 6 - Communicating research to patients and the public  
Chair: Kathy Oliver & Jonathan Punt

Plenary Lecture: Helen Bulbeck (educational consultant) to overview communicating results of MDT

09.40 - 09.50  Political lobbying (Sue Farrington-Smith)

09.50 - 10.00  TV Brain Hospital (Walton Centre), – Michael Jenkinson

10.00 - 10.10  Patient-led media (Jimmy Teens)

10.10 - 10.20  New Age of Consent or New Age of Enlightenment - the new challenge for doctors (Jonathan Punt)

10.20 - 10.30  Encouraging brain tumour tissue donation (Kathreena Kurian)

10.30 - 10.40  Chair to sum up

10.40 - 11.30  Coffee/BNOS Annual General Meeting

11.30 - 12.40  Session 7 – Clinical issues in trial development  
Chair: Paul Byrne & Geoff Pilkington

11.30 - 11.45  Plenary lecture: Glenis Wilmot (MEP)  
European Clinical Trials

11.45 - 12.00  Plenary Lecture: Ralf Herold, Senior Scientific Officer (Paediatric Medicines), European Medicines Agency  
Medicines for patients with a brain tumour - European Medicines Agency's experience and collaboration with stakeholders in neuro-oncology
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker/Institution</th>
<th>Title/Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00 - 12.10</td>
<td>Professor David Walker, CBTRC, University Of Nottingham</td>
<td>A consensus workshop to develop risk-based selection criteria for the next SIOP trial of “Sight-saving Therapy” for children with NF-1-associated optic pathway glioma (NF1-OPG)</td>
</tr>
<tr>
<td>12.10 - 12.20</td>
<td>Dr Christopher Millward, Alder Hey Children’s NHS Foundation Trust</td>
<td>Assessing ‘second-look’ tumour resectability in childhood ependymoma - A centralised review panel and classification tool for the SIOP Ependymoma II trial</td>
</tr>
<tr>
<td>12.20 - 12.30</td>
<td>Professor Susan Short, University of Leeds</td>
<td>Intravenous delivery of Oncoytic REOLYSIN® to primary and secondary brain tumours</td>
</tr>
<tr>
<td>12.30 - 12.40</td>
<td>Dr Ruman Rahman, CBTRC, University Of Nottingham</td>
<td>Delineating intra-tumour metabolomic and phospho-proteomic heterogeneity in patient glioblastomas through advanced analytical methods</td>
</tr>
<tr>
<td>12.40 - 12.50</td>
<td>Dr Jason Adhikaree, University Of Nottingham</td>
<td>Feasibility of using circulating dendritic cells in cancer vaccine treatments for glioblastoma</td>
</tr>
<tr>
<td>12.50 - 13.00</td>
<td>Professor Jonathan Finlay, Nationwide Children’s Hospital, Columbus, Ohio</td>
<td>Preliminary Results of the Prospective Feasibility CNS GCT-4 Consortium Trial for Patients with Refractory/Recurrent CNS Germ Cell Tumors (GCT)</td>
</tr>
<tr>
<td>13.00 - 13.10</td>
<td>Best poster / best oral presentation prize</td>
<td></td>
</tr>
<tr>
<td>13:10</td>
<td>Closing remarks &amp; BNOS 2016</td>
<td></td>
</tr>
</tbody>
</table>